Literature DB >> 31653669

Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol.

Augusto Azuara-Blanco1, Nicola Logan2, Niall Strang3, Kathryn Saunders4, Peter M Allen5, Ruth Weir6, Paul Doherty6, Catherine Adams6, Evie Gardner6, Ruth Hogg7, Margaret McFarland8, Jennifer Preston9, Rejina Verghis6, James J Loughman10, Ian Flitcroft11, David A Mackey12, Samantha Sze-Yee Lee12, Christopher Hammond13, Nathan Congdon7,14,15, Mike Clarke7,6.   

Abstract

BACKGROUND/AIMS: To report the protocol of a trial designed to evaluate the efficacy, safety and mechanism of action of low-dose atropine (0.01%) eye-drops for reducing progression of myopia in UK children.
METHODS: Multicentre, double-masked, superiority, placebo-controlled, randomised trial. We will enrol children aged 6-12 years with myopia of -0.50 dioptres or worse in both eyes.We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five centres. Participants will instil one drop in each eye every day for 2 years and attend a research centre every 6 months. The vehicle and preservative will be the same in both study arms.The primary outcome is SER of both eyes measured by autorefractor under cycloplegia at 2 years (adjusted for baseline). Secondary outcomes include axial length, best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y) and tolerability at 2 years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body biometry and chorioretinal thickness. Endpoints from both eyes will be pooled in combined analysis using generalised estimating equations to allow for the correlation between eyes within participant. Three years after cessation of treatment, we will also evaluate refractive error and adverse events.
CONCLUSIONS: The Childhood Atropine for Myopia Progression in the UK study will be the first randomised trial reporting outcomes of low-dose atropine eye-drops for children with myopia in a UK population. TRIAL REGISTRATION NUMBER: ISRCTN99883695, NCT03690089. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  child health (paediatrics); clinical trial; drugs; optics and refraction; treatment medical

Mesh:

Substances:

Year:  2019        PMID: 31653669     DOI: 10.1136/bjophthalmol-2019-314819

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  A machine learning-based algorithm used to estimate the physiological elongation of ocular axial length in myopic children.

Authors:  Tao Tang; Zekuan Yu; Qiong Xu; Zisu Peng; Yuzhuo Fan; Kai Wang; Qiushi Ren; Jia Qu; Mingwei Zhao
Journal:  Eye Vis (Lond)       Date:  2020-10-22

Review 2.  The Combined Effect of Low-dose Atropine with Orthokeratology in Pediatric Myopia Control: Review of the Current Treatment Status for Myopia.

Authors:  José-María Sánchez-González; Concepción De-Hita-Cantalejo; María-José Baustita-Llamas; María Carmen Sánchez-González; Raúl Capote-Puente
Journal:  J Clin Med       Date:  2020-07-24       Impact factor: 4.241

3.  Corneal Penetration of Low-Dose Atropine Eye Drops.

Authors:  Henning Austermann; Frank Schaeffel; Ute Mathis; Verena Hund; Frank Mußhoff; Focke Ziemssen; Sven Schnichels
Journal:  J Clin Med       Date:  2021-02-04       Impact factor: 4.241

Review 4.  IMI 2021 Yearly Digest.

Authors:  Monica Jong; Jost B Jonas; James S Wolffsohn; David A Berntsen; Pauline Cho; Danielle Clarkson-Townsend; Daniel I Flitcroft; Kate L Gifford; Annechien E G Haarman; Machelle T Pardue; Kathryn Richdale; Padmaja Sankaridurg; Milly S Tedja; Christine F Wildsoet; Joan E Bailey-Wilson; Jeremy A Guggenheim; Christopher J Hammond; Jaakko Kaprio; Stuart MacGregor; David A Mackey; Anthony M Musolf; Caroline C W Klaver; Virginie J M Verhoeven; Veronique Vitart; Earl L Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-04-28       Impact factor: 4.799

5.  Effect of Sunshine Duration on Myopia in Primary School Students from Northern and Southern China.

Authors:  Lin Leng; Jiafan Zhang; Sen Xie; Wenzhi Ding; Rongyuan Ji; Yuyin Tian; Keli Long; Hongliang Yu; Zhen Guo
Journal:  Int J Gen Med       Date:  2021-08-28

6.  Effect of 0.01% Atropine on Accommodation in Myopic Teenagers.

Authors:  Huixia Li; Liying Zhang; Hong Tian; Song Zhang; Xueyan Zhang; Han Zhang; Yujing Chen; Wenping Qi; Xiaoying Wu; Hongmei Jiang; Hailong Yang; Yajun Yang; Lei Liu; Guisen Zhang
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

7.  Short-Term Effects of Atropine 0.01% on the Structure and Vasculature of the Choroid and Retina in Myopic Chinese Children.

Authors:  Yuliang Wang; Xingxue Zhu; Yi Xuan; Min Wang; Xingtao Zhou; Xiaomei Qu
Journal:  Ophthalmol Ther       Date:  2022-02-20

8.  Simulations to Assess the Performance of Multifactor Risk Scores for Predicting Myopia Prevalence in Children and Adolescents in China.

Authors:  Hong Wang; Liansheng Li; Wencan Wang; Hao Wang; Youyuan Zhuang; Xiaoyan Lu; Guosi Zhang; Siyu Wang; Peng Lin; Chong Chen; Yu Bai; Qi Chen; Hao Chen; Jia Qu; Liangde Xu
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

9.  Will treating progressive myopia overwhelm the eye care workforce? A workforce modelling study.

Authors:  Gareth Lingham; James Loughman; Stella Kuzmenko; Matilda Biba; Daniel Ian Flitcroft
Journal:  Ophthalmic Physiol Opt       Date:  2022-06-21       Impact factor: 3.992

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.